Affiliation:
1. Department of Neurology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009,
Zhejiang, China
Abstract
Background:
Parkinson’s disease (PD) is the second most common neurodegenerative disease
with a significant public health burden. It is characterized by the gradual degeneration of dopamine
neurons in the central nervous system. Although symptomatic pharmacological management remains
the primary therapeutic method for PD, clinical experience reveals significant inter-individual
heterogeneity in treatment effectiveness and adverse medication responses. The mechanisms behind
the observed interindividual variability may be elucidated by investigating the role of genetic variation
in human-to-human variances in medication responses and adverse effects.
Objective:
This review aims to explore the impact of gene polymorphism on the efficacy of antiparkinsonian
drugs. The identification of factors associated with treatment effectiveness variability might
assist the creation of a more tailored pharmacological therapy with higher efficacy, fewer side outcomes,
and cheaper costs.
Methods:
In this review, we conducted a thorough search in databases such as PubMed, Web of Science,
and Google Scholar, and critically examined current discoveries on Parkinson's disease pharmacogenetics.
The ethnicity of the individuals, research methodologies, and potential bias of these
studies were thoroughly compared, with the primary focus on consistent conclusions.
Results:
This review provides a summary of the existing data on PD pharmacogenetics, identifies its limitations,
and offers insights that may be beneficial for future research. Previous studies have investigated
the impact of gene polymorphism on the effectiveness and adverse effects of levodopa. The trendiest
genes are the COMT gene, DAT gene, and DRD2 gene. However, limited study on other anti-Parkinson's
drugs has been conducted.
Conclusion:
Therefore, In order to develop an individualized precision treatment for PD, it is an inevitable
trend to carry out multi-center, prospective, randomized controlled clinical trials of PD pharmacogenomics
covering common clinical anti-PD drugs in large, homogeneous cohorts.
Funder
Zhejiang Provincial Program for Medical and Health Science Co-sponsored by Province and Ministry
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology,General Medicine
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献